Skip to main content

Table 6 Adverse events in the double-blind study

From: Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness

Adverse event

Chloroquine subjects (%)

Placebo subjects (%)

P value

Total subjects with any event

44 (76)

39 (67)

0.4107

Subjects with a serious adverse event

5 (9)

2 (3)

0.4385

Total adverse events

109 (100)

105 (100)

–

Infectious

51 (47)

42 (40)

0.0609

Allergy/immunology

5 (5)

10 (10)

0.2681

Musculoskeletal

17 (16)

15 (15)

0.8357

CNS

5 (5)

3 (3)

–

Psychiatric

5 (5)

6 (6)

–

Hematologic/neoplasm

2 (2)

2 (2)

–

Cardiovascular

2 (2)

3 (3)

–

GI

3 (3)

3 (3)

–

GU

2 (2)

2 (2)

–

Metabolic

1 (1)

6 (6)

–

Miscellaneous

0 (0)

3 (3)

–

Ocular

16 (15)

10 (10)

0.2654

Ocular details

 Retinal

3

3

–

 Lens

4

2

–

 Vision

2

0

–

 Infectious

2

0

–

 Glaucoma

2

2

–

  1. Parentheses denote %
  2. P values determined using contingency tables